Go to the list of all blogs
John Y White's Avatar
published in Blogs
Oct 06, 2026
AGNC vs NLY: Mortgage REIT Strategies Compared for Income Seekers

AGNC vs NLY: Mortgage REIT Strategies Compared for Income Seekers

Key Takeaways

  • Different business models: AGNC is a leveraged, primarily Agency-focused mortgage REIT, while NLY runs a more diversified housing finance platform spanning Agency, residential credit, and mortgage servicing rights (MSR).
  • Earnings momentum: Annaly has posted nine consecutive quarters in which earnings available for distribution (EAD) exceeded its dividend, and recently raised its payout; AGNC has delivered volatile economic returns quarter to quarter.
  • Book value trends: Both companies have grown tangible book value year over year, with AGNC up roughly 10% and NLY up around 9% versus the prior-year period.
  • Dividend profiles: AGNC pays a monthly $0.12 dividend (around a mid-teens yield), while NLY pays a quarterly dividend recently increased to $0.75 per share.
  • Leverage and risk: AGNC operates at higher "at risk" leverage (about 7.4x) than NLY's economic leverage (about 5.6x), reflecting different risk appetites.

Setting the Stage for These Two Mortgage REITs

Mortgage REITs hold a unique spot in the income space, and names like AGNC (AGNC Investment Corp.) and NLY (Annaly Capital Management) often come up in discussions. Both focus on mortgage-backed securities, yet they follow distinct paths. This comparison matters for income investors and those tracking performance amid interest-rate shifts and changing Federal Reserve signals. I also checked this using Tickeron’s AI Screener to see how the stocks line up against peers.

AGNC Investment: Agency Focus and Recent Results

AGNC Investment Corp. concentrates on Agency mortgage-backed securities guaranteed by government-sponsored entities. Its portfolio stood at roughly $97 billion at the end of the latest quarter, mostly in 30-year fixed-rate Agency MBS and TBA contracts. Performance has been uneven. The first quarter showed a negative economic return on tangible common equity of about -1.6%, tied to prepayment speeds and a narrower net interest spread. The next quarter improved to around 6.7%, helped by book value gains and steady dividends. Management noted a five-quarter stretch of positive excess returns for Agency MBS over Treasuries. The company has now paid its 75th consecutive monthly $0.12 dividend. One thing that stands out is the 7.4x leverage, which heightens sensitivity to rate moves.

Annaly Capital: Diversified Platform and Momentum

NLY operates a broader residential mortgage finance business across Agency MBS, Residential Credit, and Mortgage Servicing Rights. Its portfolio topped $109 billion, with Agency assets near $95 billion, residential credit at about $10.4 billion, and MSR around $4.1 billion. Results have been steadier, with a 5.5% economic return in the latest quarter and 6.9% for the first half. Earnings available for distribution hit $0.79 per share—the ninth straight quarter above the dividend—and the quarterly payout rose to $0.75. Book value per share reached roughly $20.15. The Residential Credit unit set records with $7.1 billion in purchases and 13 securitizations. Economic leverage stayed at about 5.6x. From what I see, the diversification helps buffer some volatility.

Head-to-Head: Business Models, Momentum, and Risk

The main difference lies in focus. AGNC stays concentrated on Agency MBS, so results hinge heavily on spreads, prepayments, and hedging. NLY spreads exposure across three areas, which can stabilize returns and add drivers like servicing income. On momentum, Annaly shows stronger dividend coverage and has raised its payout while growing book value. AGNC posted a sharper rebound in one quarter but more swings overall. Risk-wise, AGNC’s higher 7.4x leverage magnifies moves compared with NLY’s 5.6x. Both offer attractive yields, yet those reflect the sector’s rate and credit exposures. Market views on both have been shaped by policy uncertainty and MBS demand trends. I’m watching this closely as conditions evolve.

AI-Assisted View on the Pair

In my view, the factors point toward NLY for steadier positioning right now, thanks to diversification, consistent earnings coverage, book value growth, and lower leverage. That said, AGNC could deliver more upside from Agency spread recovery plus its monthly payout. The decision comes down to tolerance for concentration versus broader stability, and relative standings can shift with rate and credit changes.

Using Tickeron AI Tools in My Research

I often turn to Tickeron’s tools when comparing names like these. The Trending AI Robots section stands out because it surfaces models best suited to current conditions across strategies and timeframes. Reviewing active signals there has helped me gauge momentum on mortgage REITs without relying solely on traditional metrics. It’s a practical way to cross-check ideas before forming a view.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AGNC, NLY

Contributor

John Y White's AvatarJohn Y White|Beginner

Experienced trader focused on market analysis, identifying trading opportunities, and developing custom trading signals based on market trends, price action, and data-driven insights. Join my Trader Club to follow my latest analysis, trading ideas, and active signals: https://tickeron.com/app/trader-club/103/view?tab=active&section=trades&via=john


View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a real estate investment trust

Industry RealEstateInvestmentTrusts

Industry
Real Estate Investment Trusts
Address
7373 Wisconsin Avenue
Phone
+1 301 968-9315
Employees
53
Web
https://www.agnc.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.
I've always appreciated how Mastercard (MA) maintains a commanding position in the global payments industry, processing transactions across 3.4 billion cards at 150 million merchant locations worldwide. The network effects here create a formidable moat—increased adoption by issuers, acquirers, and consumers just reinforces its dominance. What stands out to me is how Mastercard is evolving beyond a pure processor into a services-first platform. Value-added services (VAS)—covering cybersecurity, data analytics, and consulting—are now approaching 40% of revenues and growing at double the rate of traditional payments.
MU shares are declining approximately -6.00% in premarket trading on April 2, 2026, pulling back to roughly $353.70 from the prior session's close of $376.27. The primary catalyst is a sweeping new round of tariff announcements from the Trump administration, dubbed by markets as "Liberation Day 2.0," which has sparked a broad risk-off selloff across technology and semiconductor stocks